MetaVia is trading at $1.81 (9.2% down) as investors lock in gains following a significant multi-day rally and signs of profit-taking.
- The stock recently saw strong momentum tied to enthusiasm around its DA-1726 obesity trial milestone on July 13, 2026.
- With no new fundamental updates or company-specific headlines pre-market, the current move appears to be a continued digestion of recent volatility amid a nervous biotech and tech tape.